Mark Heinen - Nov 30, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Head of Finance and Interim Chief Financial Officer
Signature
/s/ Mark Heinen
Stock symbol
BTTX
Transactions as of
Nov 30, 2022
Transactions value $
$19,512
Form type
4
Date filed
12/2/2022, 03:15 PM
Previous filing
Sep 14, 2022
Next filing
Apr 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Award $19.5K +15.7K +22.46% $1.24 85.7K Nov 30, 2022 Direct F1
holding BTTX Common Stock 2.28K Nov 30, 2022 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

Head of Finance and Interim Chief Financial Officer